131 related articles for article (PubMed ID: 14621098)
1. N-acetylcysteine is unlikely to reduce hospitalisation for chronic obstructive pulmonary disease.
Ernst P; Suissa S
Eur Respir J; 2003 Nov; 22(5):865; author reply 865-6. PubMed ID: 14621098
[No Abstract] [Full Text] [Related]
2. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease.
Gerrits CM; Herings RM; Leufkens HG; Lammers JW
Eur Respir J; 2003 May; 21(5):795-8. PubMed ID: 12765423
[TBL] [Abstract][Full Text] [Related]
3. [Is systemic administration of N-acetylcysteine effective?].
Gillissen A
Dtsch Med Wochenschr; 2003 Mar; 128(12):632. PubMed ID: 12649804
[No Abstract] [Full Text] [Related]
4. Plastic bronchitis as an unusual cause of mucus plugging in cystic fibrosis.
Mateos-Corral D; Cutz E; Solomon M; Ratjen F
Pediatr Pulmonol; 2009 Sep; 44(9):939-40. PubMed ID: 19658112
[TBL] [Abstract][Full Text] [Related]
5. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
[TBL] [Abstract][Full Text] [Related]
6. De medicamenteuze behandeling van chronisch obstructieve longziekte [Drug treatment of chronic obstructive lung disease.
Cabolet P
Ned Tijdschr Geneeskd; 1996 Aug; 140(33):1705. PubMed ID: 8776959
[No Abstract] [Full Text] [Related]
7. [Acetylcysteine in chronic obstructive pulmonary disease. Secretolytic, antioxidant or placebo?].
Randerath W; Galetke W
Med Monatsschr Pharm; 2003 Nov; 26(11):375-8. PubMed ID: 14652922
[No Abstract] [Full Text] [Related]
8. Acute exacerbations of chronic obstructive pulmonary disease.
Stey C
Ann Intern Med; 2002 Apr; 136(7):556-8; author reply 556-8. PubMed ID: 11926798
[No Abstract] [Full Text] [Related]
9. ABC of chronic obstructive pulmonary disease. Pharmacological management--oral treatment.
Currie GP; Lee DK; Lipworth BJ
BMJ; 2006 Jun; 332(7556):1497-9. PubMed ID: 16793814
[No Abstract] [Full Text] [Related]
10. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
[TBL] [Abstract][Full Text] [Related]
11. Increased hydrogen peroxide concentration in the exhaled breath condensate of stable COPD patients after nebulized N-acetylcysteine.
Rysz J; Stolarek RA; Luczynski R; Sarniak A; Wlodarczyk A; Kasielski M; Nowak D
Pulm Pharmacol Ther; 2007; 20(3):281-9. PubMed ID: 16753318
[TBL] [Abstract][Full Text] [Related]
12. N-acetylcysteine in COPD may be beneficial, but for whom?
Cazzola M; Matera MG
Lancet Respir Med; 2014 Mar; 2(3):166-7. PubMed ID: 24621673
[No Abstract] [Full Text] [Related]
13. N-acetylcysteine for COPD: the evidence remains inconclusive.
Turner RD; Bothamley GH
Lancet Respir Med; 2014 Apr; 2(4):e3. PubMed ID: 24717631
[No Abstract] [Full Text] [Related]
14. N-acetylcysteine for COPD: the evidence remains inconclusive--authors' reply.
Zheng JP; Zhong NS
Lancet Respir Med; 2014 Apr; 2(4):e3-4. PubMed ID: 24717632
[No Abstract] [Full Text] [Related]
15. Use of N-acetylcysteine for postnecrosectomy peripancreatic collections in a patient with severe, acute pancreatitis.
Narasimhan S; Khwaja HA; Dutta S; Mitchenere P
Can J Surg; 2008 Dec; 51(6):E133-4. PubMed ID: 19057727
[No Abstract] [Full Text] [Related]
16. The intravenous use of oral acetylcysteine (mucomyst) for the treatment of acetaminophen overdose.
Amirzadeh A; McCotter C
Arch Intern Med; 2002 Jan; 162(1):96-7. PubMed ID: 11784228
[No Abstract] [Full Text] [Related]
17. The sulphoxidation of S-carboxymethyl-L-cysteine in COPD.
Steventon GB; Mitchell SC
Eur Respir J; 2006 Apr; 27(4):865-6. PubMed ID: 16585098
[No Abstract] [Full Text] [Related]
18. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
19. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
20. N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease.
Sadowska AM
Ther Adv Respir Dis; 2012 Jun; 6(3):127-35. PubMed ID: 22361928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
